Contribute Try STAT+ Today

A Novartis drug that delivers a lethal dose of radiation directly to prostate cancer cells delayed tumor growth and extended survival in men with advanced disease, according to results of a late-stage clinical trial.

Treatment with what Novartis calls radioligand therapy — thankfully, because its scientific name is 177Lu-PSMA-617 — reduced the risk of death by 38% compared with standard drugs. The risk of tumor progression was cut by 60%. Both outcomes achieved the main goals of the Phase 3 study with statistical significance.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.